Imugene and JW Therapeutics Partner to Advance CAR-T and Oncolytic Virus Therapy for Solid Tumors
Imugene Limited and JW Therapeutics have announced a strategic collaboration to advance a novel combination therapy for refractory solid tumors. The partnership will evaluate Imugene’s onCARlytics oncolytic virus with JW Therapeutics’ Carteyva® CAR-T cell therapy. This initiative includes preclinical studies and a Phase 1 trial in China, aiming to explore new treatment paradigms for solid tumors. The collaboration seeks to generate impactful preclinical and clinical data.
Imugene Limited has announced a strategic collaboration with JW Therapeutics to advance a novel combination therapy for refractory solid tumors. The partnership will evaluate Imugene’s onCARlytics (CF33-CD19) oncolytic virus in combination with JW Therapeutics’ Carteyva®, an approved CD19-directed autologous CAR-T cell therapy. The initiative includes preclinical studies and a Phase 1 investigator-initiated trial in China, employing a “mark and kill” strategy where the oncolytic virus induces CD19 expression on tumor cells, making them targetable by CAR-T cells. The collaboration aims to generate impactful preclinical and clinical data to explore new treatment paradigms for solid tumors. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imugene Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN34930) on November 28, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
